Target intelligence / Profile preview

Immune system activation via KLH-conjugated tumor antigen

Molecular classification: Vaccine, Immunotherapeutic, Conjugate vaccine

Overview

Immune system activation via KLH-conjugated tumor antigen refers to a strategy in cancer immunotherapy where a weakly immunogenic tumor antigen is chemically linked (conjugated) to the highly immunogenic carrier protein Keyhole Limpet Hemocyanin (KLH). This conjugation enhances the immune system's recognition and response to the tumor antigen, facilitating both humoral and cellular immunity against cancer cells expressing that antigen.

Other names: KLH-conjugated tumor antigen vaccineTumor antigen-KLH conjugate immunotherapyId-KLH vaccineGlobo H-KLH vaccine

Mechanism of action

Enhances adaptive immune response by providing strong helper signals for weak antigens

Biological functions

Immune response activationAntigen presentationT cell activationB cell activationAntibody productionCytotoxic T lymphocyte activation

Disease associations

CancerB-cell lymphomaEpithelial cancers

Safety considerations

Potential for lack of response in patients with high disease burden or impaired immunityOverconjugation can damage key epitopes if not carefully controlledPotential for off-target immune responses

Biomarkers

Anti-KLH antibody titersTumor antigen-specific IgM/IgG/IgA levelsCD8+ T cell activityMature dendritic cells loaded with KLH-conjugates induce higher levels of specific antibodies compared to immature DCs.

Beyond the preview

Go deeper on Immune system activation via KLH-conjugated tumor antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune system activation via KLH-conjugated tumor antigen.

Explore the full profile